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Abstract
Introduction. Wells` syndrome (eosinophilic cellulitis) is a chronic, recurrent disease characterized by episodes of erythematous and edematous plaques or nodules with occasional development of hemorrhagic bullae, on the trunk and limbs. Eosinophilic granulomatosis with polyangiitis formerly known as Churg-Strauss syndrome is a specific variant of the group of diseases characterized by necrotizing vasculitis of small to mediumsized blood vessels affecting multiple organ systems. The association of Wells` syndrome and eosinophilic granulomatosis with polyangiitis is very rare and according to our knowledge has been reported in only ten patients. Case report. We present a case of a 34-year-old woman with a 3-year history of periodical onset of erythematous plaques on trunk and edematous plaque that clinically resembling cellulitis on her lower limbs. The patient reported a one-year history of asthma, rhinosinusitis and nasal polyposis. Skin biopsy revealed the presence of diffuse eosinophilic infiltrate in the dermis accompanied by characteristic "flame figures". Further investigation showed peripheral blood eosinophilia (22.6%), bilateral maxillary sinusitis, presence of eosinophil infiltrates and microabscesses in bronchial wall and pericapillary eosinophil infiltrates in lung shown by bronchoscopy and transbronchial biopsy, respectively. Treatment was started with methylprednisolone 0.5 mg/kg/day and the dose was gradually tapered for the following twelve weeks. Complete remission of skin changes was achieved but new lesions appeared in the last two years which required repeated treatment. Conclusion. Association of these syndromes is unusual and may be based on the common pathogenetic background. We hypothesize that Wells` syndrome could be prior stage of eosinophilic granulomatosis with polyangiitis and that patients should be evaluated for eosinophilic granulomatosis with polyangiitis since these two diseases overlap in clinical and laboratory findings. To our knowledge, the association between WS and EGPA has been reported in ten patients. These syndromes may have a common pathogenetic mechanism with hypersensitive reaction to the underlying cause including allergens, insect bites, infections, vaccinations, medications and malignancy [4] [5] [6] [7] [8] [9] [10] [11] [12] .
Case report
A 34-year-old woman with a 3-year history of periodical onset of erythematous plaques on trunk and edematous plaque that clinically resembling cellulitis on the lower limbs was admitted to our department (Figs. 1a and 1b). At the time, lesions were extremely pruritic and occasionally accompanied by burning sensation. Previously, the patient had been treated with antihistamines and occasionally with short-term administration of prednisone.
However, she had had several exacerbations following each discontinuation of prednisone.
The patient denied taking any additional medications, presence of fever, weight loss or joint pain. She reported a one-year history of asthma, rhinosinusitis and nasal polyposis. To treat asthma, she had been taking inhaled corticosteroids and beta-2-agonists. Pulmonary function tests showed normal spirometry finding, transfer factor for carbon monoxide (70%) and transfer coefficient (72%) were reduced; oxygen saturation was 97%.
Radiological examination revealed bilateral maxillary sinusitis (Fig. 2) . The electromyoneurographic examination was performed and neuropathy was excluded.
Peripheral blood smear and bone marrow biopsy have ruled out a hematological disorder.
Chest radiography and heart ultrasonography were normal. However, microscopic examination of bronchoalveolar lavage confirmed eosinophilia (63%). Histopathologic findings of bronchoscopic biopsy revealed fragments with abundant eosinophilic and lymphocytic infiltrates as well as the foci of eosinophilic microabscesses. Pericapillary eosinophilic infiltrates affecting the lung interstitial were observed with transbronchial biopsy which could be a histologic sign of vasculitis.
WS associated with EGPA was confirmed and the initial treatment with methylprednisolone was introduced at a dose of 0.5 mg/kg/day. For the following 12 weeks, the dose was gradually reduced to the maintenance dose of 5 mg every other day that was prescribed for the period of one year. The administered therapy was sufficient to manage the condition for the subsequent six years, after which the lesions appeared again and the treatment was reintroduced. Any attempt to discontinue the treatment led to reappearance of skin changes.
Additional treatment with inhaled budesonide/formoterol and supplementation with calcium 1000 mg/day and vitamin D at the dosage of 800 IU/day were prescribed. Regarding treatment, patient had a favorable response to methylprednisolone and remission was achieved and maintained for six years. However, in the last two years, there was reappearance of skin lesions and methylprednisolone has been re-introduced with tapering to 5 mg every other day, up until now. Nevertheless, any attempt to discontinue the drug led to reappearance of skin lesions that were mild compared to the initial presentation of the disease. Additional treatment with inhaled budesonide/formoterol and supplementation with calcium 1000 mg/day and vitamin D at the dosage of 800 IU/day were prescribed.
Conclusion
Association of these syndromes is unusual and may be based on the common pathogenetic background. We hypothesize that WS could be prior stage of EGPA and that patients should be evaluated for EGPA since these two diseases overlap in clinical and laboratory findings. Corticosteroids are the first line of treatment and usually sufficient for patients who do not have severe organ involvement as in the case of our patient were we achieved long term remission. Additional immunosuppressive or biological agents may be necessary in cases of severe organ damage, treatment failure and frequent relapses.
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